Mesoblast gains US FDA OK for Phase III mesenchymal precursor cell study
This article was originally published in Scrip
Executive Summary
The US FDA has given Mesoblast and its US partner Cephalon the go-ahead for a Phase III trial of the Australian firm's mesenchymal precursor cells (MPCs) in patients with hematologic malignancies.